Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.58 USD | +0.18% | +0.09% | +3.96% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With a P/E ratio at 11.22 for the current year and 8.36 for next year, earnings multiples are highly attractive compared with competitors.
- The company has a low valuation given the cash flows generated by its activity.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.96% | 1.91B | C- | ||
+33.46% | 701B | C+ | ||
+26.24% | 570B | B | ||
+0.93% | 381B | C+ | ||
+21.03% | 334B | B- | ||
+17.51% | 322B | C+ | ||
+0.74% | 209B | B+ | ||
+2.95% | 212B | B- | ||
-6.05% | 205B | A+ | ||
-3.61% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Harmony Biosciences Holdings, Inc. - Nasdaq
- Ratings Harmony Biosciences Holdings, Inc.